Mp09-14 Sarcopenia Is a Factor for Unsatisfied Medical Treatment of Lower Urinary Tract Symptoms in Elderly Men Aged 75 Years or Older– Analysis Using Sarc-F

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology, Evaluation & Medical Non-surgical Therapy (MP09)1 May 2024MP09-14 SARCOPENIA IS A FACTOR FOR UNSATISFIED MEDICAL TREATMENT OF LOWER URINARY TRACT SYMPTOMS IN ELDERLY MEN AGED 75 YEARS OR OLDER– ANALYSIS USING SARC-F Naoki Wada, Haruka Takagi, Masaya Nagabuchi, Tsubasa Hatakeyama, Shun Morishita, Ryoken Tsunekawa, Takeya Kitta, and Hidehiro Kakizaki Naoki WadaNaoki Wada , Haruka TakagiHaruka Takagi , Masaya NagabuchiMasaya Nagabuchi , Tsubasa HatakeyamaTsubasa Hatakeyama , Shun MorishitaShun Morishita , Ryoken TsunekawaRyoken Tsunekawa , Takeya KittaTakeya Kitta , and Hidehiro KakizakiHidehiro Kakizaki View All Author Informationhttps://doi.org/10.1097/01.JU.0001008920.55771.18.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Frail or sarcopenia is a significant issue in the super-aged society. We assume that sarcopenia has some impacts on the outcome of medical treatments for lower urinary tract symptoms (LUTS) in the elderly. There are few data analyzing the relationship between sarcopenia and LUTS. Thus, we investigated if sarcopenia affects the treatment outcomes in elderly patients receiving medical therapy for LUTS. METHODS: The subjects were male LUTS patients aged 75 years or older who had not changed their medication for one year or more. The current conditions were estimated using IPSS, overactive bladder symptoms score (OABSS), and screening tool for sarcopenia (SARC-F). We also evaluated prostatic volume (PV), serum testosterone, body composition (amount of muscle) and grip strength. SARC-F≧4 is defined as sarcopenia. RESULTS: Fifty-five patients (mean age 80 years, ranging 75-92) were included in this research. Sixteen patients (29.0%) were categorized into sarcopenia by SARC-F. All patients received α1 blocker or tadalafil. Dutasteride and OAB medication (anticholinergics or β3 agonist) were prescribed to 27 (49.1%) and 19 (34.5%), respectively. The mean grip strength was significantly lower in sarcopenia group than non-sarcopenia group (25.8±4.6 vs 29.9±7.0 kg, p=0.014). SARC-F has a negative correlation with the grip strength (r=-0.42) and PV (r=-0.29), and a positive correlation with IPSS-total (r=0.31) and IPSS-QOL score (r=0.32). The mean IPSS-total (15.0±7.3 vs 10.3±7.0, p=0.035) and IPSS-QOL (3.6±1.1 vs 2.8±1.1, p=0.020) were significantly higher in sarcopenia group than non-sarcopenia group (Figure 1). The non-sarcopenia group had larger PV (44.8±19.3 vs 26.3±16.0 ml, p=0.001) and higher testosterone level (499±245 vs 380±112 ng/dl, p=0.086) compared with sarcopenia group, whereas the percentage of patients taking dutasteride was higher in non-sarcopenia group than sarcopenia group (59% vs 25%). Multivariate analysis revealed that only SARC-F was a significant factor affecting IPSS-total of 8 or higher despite medical treatments for one year or more (OR 1.86, 95% CI: 1.19-2.90, p=0.006). CONCLUSIONS: Sarcopenia screened by SARC-F is a significant factor for unsatisfied medical treatment of LUTS in elderly men aged 75 years or older. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e132 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Naoki Wada More articles by this author Haruka Takagi More articles by this author Masaya Nagabuchi More articles by this author Tsubasa Hatakeyama More articles by this author Shun Morishita More articles by this author Ryoken Tsunekawa More articles by this author Takeya Kitta More articles by this author Hidehiro Kakizaki More articles by this author Expand All Advertisement PDF downloadLoading ...